166 related articles for article (PubMed ID: 16684964)
21. Signal transduction of IL-6, leukemia-inhibitory factor, and oncostatin M: structural receptor requirements for signal attenuation.
Anhuf D; Weissenbach M; Schmitz J; Sobota R; Hermanns HM; Radtke S; Linnemann S; Behrmann I; Heinrich PC; Schaper F
J Immunol; 2000 Sep; 165(5):2535-43. PubMed ID: 10946280
[TBL] [Abstract][Full Text] [Related]
22. The protein tyrosine phosphatase, Shp2, is required for the complete activation of the RAS/MAPK pathway by brain-derived neurotrophic factor.
Easton JB; Royer AR; Middlemas DS
J Neurochem; 2006 May; 97(3):834-45. PubMed ID: 16573649
[TBL] [Abstract][Full Text] [Related]
23. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth.
Bertotti A; Comoglio PM; Trusolino L
J Cell Biol; 2006 Dec; 175(6):993-1003. PubMed ID: 17158954
[TBL] [Abstract][Full Text] [Related]
24. Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.
Robinson LJ; Xue J; Corey SJ
Exp Hematol; 2005 Apr; 33(4):469-79. PubMed ID: 15781338
[TBL] [Abstract][Full Text] [Related]
25. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes.
Nakaoka Y; Nishida K; Fujio Y; Izumi M; Terai K; Oshima Y; Sugiyama S; Matsuda S; Koyasu S; Yamauchi-Takihara K; Hirano T; Kawase I; Hirota H
Circ Res; 2003 Aug; 93(3):221-9. PubMed ID: 12855672
[TBL] [Abstract][Full Text] [Related]
26. Modulation of insulin-stimulated glycogen synthesis by Src Homology Phosphatase 2.
Ouwens DM; van der Zon GC; Maassen JA
Mol Cell Endocrinol; 2001 Apr; 175(1-2):131-40. PubMed ID: 11325523
[TBL] [Abstract][Full Text] [Related]
27. The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
Voena C; Conte C; Ambrogio C; Boeri Erba E; Boccalatte F; Mohammed S; Jensen ON; Palestro G; Inghirami G; Chiarle R
Cancer Res; 2007 May; 67(9):4278-86. PubMed ID: 17483340
[TBL] [Abstract][Full Text] [Related]
28. [SHP2 and MKP5 in P2Y purinergic receptor-mediated prostate cancer invasion].
He HY; Zheng J; Li Y; Heng WJ; Fang WG
Zhonghua Bing Li Xue Za Zhi; 2005 May; 34(5):288-92. PubMed ID: 16181551
[TBL] [Abstract][Full Text] [Related]
29. Regulation of cytotoxic T lymphocyte-associated molecule-4 by Src kinases.
Chuang E; Lee KM; Robbins MD; Duerr JM; Alegre ML; Hambor JE; Neveu MJ; Bluestone JA; Thompson CB
J Immunol; 1999 Feb; 162(3):1270-7. PubMed ID: 9973379
[TBL] [Abstract][Full Text] [Related]
30. Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML.
Reindl C; Bagrintseva K; Vempati S; Schnittger S; Ellwart JW; Wenig K; Hopfner KP; Hiddemann W; Spiekermann K
Blood; 2006 May; 107(9):3700-7. PubMed ID: 16410449
[TBL] [Abstract][Full Text] [Related]
31. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms-like tyrosine kinase 3 (FLT3).
Murata K; Kumagai H; Kawashima T; Tamitsu K; Irie M; Nakajima H; Suzu S; Shibuya M; Kamihira S; Nosaka T; Asano S; Kitamura T
J Biol Chem; 2003 Aug; 278(35):32892-8. PubMed ID: 12815052
[TBL] [Abstract][Full Text] [Related]
32. Molecular basis for positive and negative signaling by the natural killer cell receptor 2B4 (CD244).
Eissmann P; Beauchamp L; Wooters J; Tilton JC; Long EO; Watzl C
Blood; 2005 Jun; 105(12):4722-9. PubMed ID: 15713798
[TBL] [Abstract][Full Text] [Related]
33. Deoxycholic acid differentially regulates focal adhesion kinase phosphorylation: role of tyrosine phosphatase ShP2.
Khare S; Holgren C; Samarel AM
Am J Physiol Gastrointest Liver Physiol; 2006 Dec; 291(6):G1100-12. PubMed ID: 16920701
[TBL] [Abstract][Full Text] [Related]
34. Regulation of neuregulin-mediated acetylcholine receptor synthesis by protein tyrosine phosphatase SHP2.
Tanowitz M; Si J; Yu DH; Feng GS; Mei L
J Neurosci; 1999 Nov; 19(21):9426-35. PubMed ID: 10531446
[TBL] [Abstract][Full Text] [Related]
35. Scaffolding protein Gab2 mediates differentiation signaling downstream of Fms receptor tyrosine kinase.
Liu Y; Jenkins B; Shin JL; Rohrschneider LR
Mol Cell Biol; 2001 May; 21(9):3047-56. PubMed ID: 11287610
[TBL] [Abstract][Full Text] [Related]
36. Flt3 ligand induces tyrosine phosphorylation of gab1 and gab2 and their association with shp-2, grb2, and PI3 kinase.
Zhang S; Broxmeyer HE
Biochem Biophys Res Commun; 2000 Oct; 277(1):195-9. PubMed ID: 11027663
[TBL] [Abstract][Full Text] [Related]
37. The cytoplasmic tyrosine kinase Pyk2 as a novel effector of fibroblast growth factor receptor 3 activation.
Meyer AN; Gastwirt RF; Schlaepfer DD; Donoghue DJ
J Biol Chem; 2004 Jul; 279(27):28450-7. PubMed ID: 15105428
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation.
Razumovskaya E; Masson K; Khan R; Bengtsson S; Rönnstrand L
Exp Hematol; 2009 Aug; 37(8):979-89. PubMed ID: 19477218
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-6-induced proliferation of pre-B cells mediated by receptor complexes lacking the SHP2/SOCS3 recruitment sites revisited.
Friederichs K; Schmitz J; Weissenbach M; Heinrich PC; Schaper F
Eur J Biochem; 2001 Dec; 268(24):6401-7. PubMed ID: 11737194
[TBL] [Abstract][Full Text] [Related]
40. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor.
Zhao M; Kiyoi H; Yamamoto Y; Ito M; Towatari M; Omura S; Kitamura T; Ueda R; Saito H; Naoe T
Leukemia; 2000 Mar; 14(3):374-8. PubMed ID: 10720129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
